Clinical Trial Update: Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluated celecoxib as a radiosensitizer with chemoradiation for head and neck cancer; results have been posted after study completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Celecoxib (Celecoxib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-04-25